{"symbol": "SPHS", "companyName": "Sophiris Bio Inc.", "exchange": "NASDAQ Capital Market", "industry": "Biotechnology", "website": "http://www.sophirisbio.com", "description": "Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in research and development of products for the treatment of urological diseases. It is developing topsalysin (PRX302) for treatment of benign prostatic hyperplasia.", "CEO": "Randall E. Woods", "issueType": "cs", "sector": "Healthcare", "tags": ["Healthcare", "Biotechnology"]}